Pharmafile Logo
Pharmafocus logo
Advanced Search

Ionis

Showing 13 posts of 13 posts found.

shutterstock_38078521

Akcea and Ionis’ Waylivra nets CHMP approval in ultra-rare familial chylomicronaemia syndrome

March 5, 2019
Manufacturing and Production, Sales and Marketing Akcea, FCS, Ionis, familial chylomicronemia syndrome, pharma, rare disease

Akcea Therapeutics and Ionis Pharmaceuticals have announced that their investigational therapy Waylivra (volanesorsen) has been recommended by the EMA’s Committee …

News

Ionis/Akcea’s ultra-rare disease drug rejected by FDA

August 28, 2018
Manufacturing and Production, Sales and Marketing Akcea, FDA, Ionis, familial chylomicronemia syndrome, pharma, rare disease

The FDA has opted to refuse approval to Akcea and Ionis’ Waylivra (volanesorsen) for the treatment of the ultra-rare hereditary …

News
biogen_idec_hillerod_2008

Biogen boosts pipeline with $1bn Ionis deal

April 23, 2018
Sales and Marketing Biogen, Ionis, Spinraza, biotech, drugs, pharma, pharmaceutical

Somewhat unusually for an early drug development deal, Biogen has put down a serious amount of cash up-front in its …

News
astrazeneca_logo_building

AZ licenses kidney drug from Ionis for $330m

February 21, 2018
Research and Development, Sales and Marketing AstraZeneca, Ionis, Isis, biotech, drugs, kidney, pharma, pharmaceutical

AstraZeneca continues to build on its relationship with San Diego-based Ionis Pharmaceuticals, this time by agreeing a licensing deal for …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

December 15, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ionis, Sanofi, Teva, haemophilia, pharma, top ten

Just 10 days away from Christmas, and big news is still flowing in the industry. Sanofi remains embroiled in scandal …

News
brainss

Ionis scores huge breakthrough in Huntington’s, Roche licenses drug

December 12, 2017
Manufacturing and Production, Research and Development Ionis, Roche, biotech, drugs, pharma, pharmaceutical

Ionis Pharmaceuticals has revealed findings from its Phase 1/2a study into a treatment for Huntington’s disease and the strong data …

News

EMA gives positive opinion on Biogen’s spinal muscular atrophy drug Spinraza

April 25, 2017
Manufacturing and Production, Sales and Marketing Biogen, Ionis, Spinraza, spinal muscular atrophy

Biogen has revealed that Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA) , has received a positive opinion from …

News
novartis_window

Novartis and Ionis enter $1bn cardiovascular drug deal

January 6, 2017
Medical Communications, Research and Development, Sales and Marketing Akcea, Akcea Therapeutics, Ionis, Ionis Pharmaceuticals, cardiovascular

Ionis Pharmaceuticals and one of its wholly-owned subsidiaries Akcea Therapeutics have entered into a partnership with Novartis worth potentially more …

News
ionis

Ionis achieves successful Phase 3 trial to treat rare diseases

December 19, 2016
Manufacturing and Production, Research and Development Akcea, Ionis, rare disease

Ionis Pharmaceutial announced that the results of a Phase 3 trial into its treatment for hypertriglyceridemia met its primary endpoint. …

News
astrazeneca_building_white

AZ secures rights from Ionis for first-ever antisense KRAS cancer drug in $165m deal

December 19, 2016
Research and Development, Sales and Marketing AstraZeneca, Ionis, KRAS

AstraZeneca has paid a $28 million milestone payment in its partnership with Ionis Pharmaceuticals over the licensing rights to anticancer …

News
biogen_austria_238

Biogen and Ionis’ spinal muscular atrophy drug meets primary endpoint

November 7, 2016
Manufacturing and Production, Research and Development Biogen, Ionis, spinal muscular atrophy

Biogen and Ionis Pharmaceuticals have released news that their investigational treatment for spinal muscular atrophy (SMA), Spinraza (nusinersen), met the …

News
biogen_austria_238

Success for Biogen, Ionis as spinal muscular atrophy drug performs in Phase III

August 2, 2016
Manufacturing and Production, Research and Development Biogen, Ionis, phase III, spinal muscular atrophy

Biogen and Ionis Pharmaceuticals have announced that their spinal muscular atrophy treatment, nusinersen, met its primary endpoint at an interim …

News
Ionis logo

ISIS Pharma changes name to Ionis to avoid ‘distracting’ militant association

December 21, 2015
Sales and Marketing Ionis, Isis Pharmaceuticals, branding, marketing, rebrand

After months of discussion, ISIS Pharmaceuticals has changed its name to Ionis to free itself from the fear of confusion …

News

Latest content

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share

September 27, 2023

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023